SG11202112355VA - Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications - Google Patents
Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applicationsInfo
- Publication number
- SG11202112355VA SG11202112355VA SG11202112355VA SG11202112355VA SG11202112355VA SG 11202112355V A SG11202112355V A SG 11202112355VA SG 11202112355V A SG11202112355V A SG 11202112355VA SG 11202112355V A SG11202112355V A SG 11202112355VA SG 11202112355V A SG11202112355V A SG 11202112355VA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- therapeutic applications
- compounds targeting
- targeting proteins
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852844P | 2019-05-24 | 2019-05-24 | |
| PCT/US2020/034264 WO2020242960A1 (en) | 2019-05-24 | 2020-05-22 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112355VA true SG11202112355VA (en) | 2021-12-30 |
Family
ID=71092611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112355VA SG11202112355VA (en) | 2019-05-24 | 2020-05-22 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11345712B2 (es) |
| EP (1) | EP3976623A1 (es) |
| JP (1) | JP2022533260A (es) |
| KR (1) | KR20220023343A (es) |
| CN (1) | CN114502543A (es) |
| AU (1) | AU2020283744A1 (es) |
| CA (1) | CA3140078C (es) |
| EA (1) | EA202192910A1 (es) |
| IL (1) | IL288204A (es) |
| MX (1) | MX2021014345A (es) |
| SG (1) | SG11202112355VA (es) |
| TW (1) | TW202110818A (es) |
| WO (1) | WO2020242960A1 (es) |
| ZA (1) | ZA202109124B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| EP4069228A4 (en) * | 2019-12-06 | 2024-04-17 | Celgene Corp | PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE |
| TW202136273A (zh) * | 2019-12-12 | 2021-10-01 | 美商拜歐斯瑞克斯公司 | Pde4抑制劑、醫藥組合物及治療應用 |
| TW202227427A (zh) | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1蛋白降解劑、其醫藥組合物及其治療應用 |
| US20240050428A1 (en) * | 2020-10-07 | 2024-02-15 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
| EP4259621A1 (en) | 2020-12-14 | 2023-10-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| KR20230167067A (ko) * | 2021-04-05 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물 |
| JP2024521966A (ja) * | 2021-06-08 | 2024-06-04 | ハンチョウ グルビオ ファーマシューティカル カンパニー，リミティド | イソインドリノン化合物およびその用途 |
| CN117440948A (zh) * | 2021-06-28 | 2024-01-23 | 成都分迪药业有限公司 | 酰胺类化合物及其用途 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023070120A1 (en) * | 2021-10-22 | 2023-04-27 | Biotheryx, Inc. | Ketoamides for treating malignancy |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023122581A2 (en) * | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| CN114835680A (zh) * | 2022-04-29 | 2022-08-02 | 成都分迪药业有限公司 | 卤素取代异吲哚啉化合物及其应用 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| US20240158370A1 (en) * | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US9938254B2 (en) * | 2016-01-08 | 2018-04-10 | Celgene Corporation | Antiproliferative compounds, and their pharmaceutical compositions and uses |
| CN108069959A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
| JP2020504711A (ja) * | 2016-12-21 | 2020-02-13 | バイオセリックス， インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
| WO2018169777A1 (en) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| CA3106239A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
-
2020
- 2020-05-22 JP JP2021569449A patent/JP2022533260A/ja active Pending
- 2020-05-22 WO PCT/US2020/034264 patent/WO2020242960A1/en unknown
- 2020-05-22 TW TW109117256A patent/TW202110818A/zh unknown
- 2020-05-22 EP EP20732707.3A patent/EP3976623A1/en active Pending
- 2020-05-22 CA CA3140078A patent/CA3140078C/en active Active
- 2020-05-22 KR KR1020217039259A patent/KR20220023343A/ko unknown
- 2020-05-22 CN CN202080052899.5A patent/CN114502543A/zh active Pending
- 2020-05-22 MX MX2021014345A patent/MX2021014345A/es unknown
- 2020-05-22 EA EA202192910A patent/EA202192910A1/ru unknown
- 2020-05-22 AU AU2020283744A patent/AU2020283744A1/en not_active Abandoned
- 2020-05-22 SG SG11202112355VA patent/SG11202112355VA/en unknown
- 2020-05-26 US US16/882,750 patent/US11345712B2/en active Active
-
2021
- 2021-11-16 ZA ZA2021/09124A patent/ZA202109124B/en unknown
- 2021-11-17 IL IL288204A patent/IL288204A/en unknown
-
2022
- 2022-05-30 US US17/804,566 patent/US20220298172A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL288204A (en) | 2022-01-01 |
| CA3140078C (en) | 2023-11-28 |
| US20220298172A1 (en) | 2022-09-22 |
| ZA202109124B (en) | 2023-10-25 |
| EP3976623A1 (en) | 2022-04-06 |
| CN114502543A (zh) | 2022-05-13 |
| JP2022533260A (ja) | 2022-07-21 |
| US11345712B2 (en) | 2022-05-31 |
| AU2020283744A1 (en) | 2021-12-09 |
| US20200369679A1 (en) | 2020-11-26 |
| CA3140078A1 (en) | 2020-12-03 |
| KR20220023343A (ko) | 2022-03-02 |
| WO2020242960A1 (en) | 2020-12-03 |
| TW202110818A (zh) | 2021-03-16 |
| EA202192910A1 (ru) | 2022-03-18 |
| MX2021014345A (es) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288204A (en) | Protein-targeted compounds and their pharmaceutical preparations and their medical applications | |
| EP3638248A4 (en) | CONJUGATES OF PHARMACEUTICAL INGREDIENTS | |
| EP4045480A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| IL272638A (en) | History of quinoxaline, their preparation and pharmaceutical preparations containing them | |
| GB2595109B (en) | Pharmaceutical delivery compositions and uses thereof | |
| EP3675860A4 (en) | SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE | |
| IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL285421A (en) | History of indazolyl-isoxazole, their preparation and pharmaceutical preparations containing them | |
| IL285674A (en) | Pharmaceutical formulations | |
| EP3851121A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY | |
| EP4023227A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS APPLICATION | |
| IL290894A (en) | pharmaceutical preparation | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| EP3777866A4 (en) | PHARMACEUTICAL COMPOSITION AND APPLICATION OF THE LATTER | |
| EP3773730A4 (en) | Drug delivery formulations | |
| IL277632A (en) | CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| EP4056565A4 (en) | ANTI-LIVER DRUGS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL291283A (en) | Formulations for drug delivery | |
| IL280989A (en) | Pharmaceutical preparations that include integration-promoting peptides | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| FI3908321T3 (fi) | Farmaseuttinen koostumus | |
| GB201906473D0 (en) | Pharmaceutical formulation | |
| GB201915829D0 (en) | Compounds, compositions and therapeutic uses thereof |